BofA Securities Maintains Henry Schein(HSIC.US) With Sell Rating
Bank of America Securities Sticks to Their Sell Rating for Henry Schein (HSIC)
CFRA Initiates Henry Schein(HSIC.US) With Sell Rating, Announces Target Price $67
Henry Schein Analyst Ratings
Evercore Maintains Henry Schein(HSIC.US) With Hold Rating, Raises Target Price to $74
Evercore ISI Adjusts Price Target on Henry Schein to $74 From $70, Maintains In Line Rating
Henry Schein Analyst Ratings
Barrington Research Maintains Outperform on Henry Schein, Maintains $82 Price Target
Barrington Maintains Henry Schein(HSIC.US) With Buy Rating, Maintains Target Price $82
Buy Rating Affirmed for Henry Schein Amid Aggressive Share Repurchase and Strategic Growth Initiatives
Henry Schein Analyst Ratings
JPMorgan Adjusts Price Target on Henry Schein to $80 From $88, Maintains Overweight Rating
Stifel Adjusts Price Target on Henry Schein to $75 From $85
Henry Schein Analyst Ratings
Barrington Research Maintains Outperform on Henry Schein, Lowers Price Target to $82
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN) and Henry Schein (HSIC)
Henry Schein (HSIC) Faces Sell Rating Amid Slow Recovery and Revised Financial Forecasts
Analysts Conflicted on These Healthcare Names: Henry Schein (HSIC), Zymeworks (ZYME) and Rocket Pharmaceuticals (RCKT)
Hold Rating on Henry Schein Amidst Revised Guidance and Market Uncertainties
Leerink Partners Maintains Henry Schein(HSIC.US) With Hold Rating